← Back to Clinical Trials
Recruiting Phase 3 NCT06387290

NCT06387290 Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06387290
Status Recruiting
Phase Phase 3
Sponsor University of Utah
Condition Chronic Pain
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2025-02-25
Primary Completion 2028-05-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Mindfulness Oriented Recovery EnhancementPatient-Centered Chronic Pain Management Visits

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 300 participants in total. It began in 2025-02-25 with a primary completion date of 2028-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary aim of this implementation-effectiveness trial is to examine the effectiveness of Mindfulness-Oriented Recovery Enhancement (MORE) and patient-centered chronic pain management visits in primary care as interventions to reduce chronic pain, improve quality of life, and reduce opioid-related harms among chronic pain patients on long-term opioid therapy.

Eligibility Criteria

Inclusion Criteria: * Age 18 + * Current chronic pain diagnosis (pain for ≥3 months) determined by physician assessment * Prescribed long-term opioid therapy (≥3 months) * Score \>=3 on the Pain Enjoyment General Activity scale * Score \>=9 on the Current Opioid Misuse Measure OR lifetime psychiatric or substance use disorder diagnosis OR benzodiazepine use OR history of overdose OR patient or physician determination that risks of opioid use may outweigh the benefits of opioid use Exclusion Criteria: * Chronic pain due to a cancer diagnosis * Active suicidal intent, schizophrenia, psychotic disorder * Prior experience with Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, Mindfulness-Based Relapse Prevention, or Mindfulness-Oriented Recovery Enhancement

Contact & Investigator

Central Contact

Hannah Pfeffer, MSW

✉ hapfeffer@health.ucsd.edu

📞 619-500-4668

Frequently Asked Questions

Who can join the NCT06387290 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06387290 trial and what does that mean for participants?

Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 300 participants.

Is NCT06387290 currently recruiting?

Yes, NCT06387290 is actively recruiting participants. Contact the research team at hapfeffer@health.ucsd.edu for enrollment information.

Where is the NCT06387290 trial being conducted?

This trial is being conducted at La Jolla, United States, New Brunswick, United States, Salt Lake City, United States.

Who is sponsoring the NCT06387290 clinical trial?

NCT06387290 is sponsored by University of Utah. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology